Metabolism of furazolidone: alternative pathways and modes of toxicity in different cell lines

I De Angelis1, L Rossi, J Z Pedersen

  • 1Istituto Superiore di Sanità, Laboratorio di Tossicologia Comparata ed Ecotossicologia, Rome, Italy.

Insights

Furazolidone

Area of Science:

  • Cellular biology
  • Pharmacology
  • Toxicology

Background:

  • Furazolidone is an antimicrobial nitrofuran drug.
  • Understanding its cellular metabolism and cytotoxicity is crucial for drug safety.
  • Variations in cellular response to drugs can impact efficacy and side effects.

Purpose of the Study:

  • To investigate the metabolism and cytotoxicity of furazolidone across different cell lines.
  • To compare free radical production, metabolite patterns, and cellular damage mechanisms.
  • To assess the role of glutathione in furazolidone's protective effects.

Main Methods:

  • Comparative study using Caco-2, HEp-2, and V79 cell lines.
  • Analysis of free radical production, metabolite profiles, and bound residue formation.
  • Assessment of cellular replication inhibition, colony-forming ability under hypoxia, and glutathione levels.

Main Results:

  • All cell lines produced similar nitro-anion radicals; metabolic breakdown varied significantly.
  • HEp-2 cells showed impaired colony-forming ability under hypoxia, suggesting DNA damage.
  • Caco-2 cells exhibited glutathione depletion and reduced viability upon furazolidone exposure, unlike V79 and HEp-2 cells.

Conclusions:

  • Furazolidone's cytotoxicity is mediated by diverse mechanisms linked to specific metabolic pathways.
  • Cellular response to furazolidone is cell-type dependent, not attributable to a single toxic intermediate.
  • Caco-2 cells detoxify furazolidone via glutathione, V79 cells form protein-bound residues, and HEp-2 cells may experience DNA-related damage.

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...